Inhalation Drug Delivery News
-
eXmoor Pharma And Vaccine Developer Imophoron Sign Process Development Partnership
2/22/2023
eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and Imophoron, the developer of a novel, next generation thermostable vaccine platform, ADDomer, to combat present and future infectious diseases, today announce the signature of a strategic process development partnership that includes a future GMP manufacturing route.
-
Catalent And Ethicann Sign Development And License Agreement For New Fast-Dissolve Cannabinoid-Based Treatments
1/12/2023
Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology.
-
Formulated Solutions Signs Agreement To Acquire 455,000ft2 US FDA Approved Drug Production Site
12/19/2022
Formulated Solutions, a Florida-based Contract Development and Manufacturing Organization (CDMO) supporting consumer-centric innovation, expert development, and cost-effective production of consumer healthcare solutions, announced an agreement to acquire a newly updated 455,000 ft2 FDA approved pharmaceutical liquids, semi solids, aerosol, BoV, and metered dose nasal spray production facility located in Cleveland, TN.
-
Hovione And GEA Announce A Strategic Collaboration To Advance Continuous Tableting
12/14/2022
Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years.
-
Kindeva And Meridian Combine: Create Leading Drug-Device Combination Product CDMO
12/13/2022
The combination has created a leading global contract development and manufacturing organization (“CDMO”) focused on drug-device combination products. The combination will operate under the Kindeva name, with Meridian operating as, “Meridian Medical Technologies, a Kindeva Company”.
-
Recipharm Invests In Its Single Dose Nasal Platform Capabilities
11/30/2022
Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose Xtra (single dose) nasal delivery platform.
-
Kindeva Drug Delivery And Meridian Medical Technologies To Combine
11/15/2022
Kindeva Drug Delivery announced that it will combine with Meridian Medical Technologies. The combination will create a leading global drug-device combination product CDMO. Kindeva and Meridian will continue to operate independently until closing.
-
Aptar Pharma Announces Collaboration With TFF Pharmaceuticals
11/7/2022
Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a collaboration with TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform.
-
EpiVax Joins Intravacc, CEPI On Project To Develop Universal Betacoronavirus Vaccine
10/31/2022
EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
-
Micro-Sphere Expands HPAPI Capabilities At Swiss Site
10/24/2022
Spray drying specialist and capsule filling service contract development and manufacturing organisation (CDMO) Micro-Sphere has invested over €5M to expand its GMP manufacturing capabilities at its facility in Monteggio, Switzerland.